SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study

İmre, Eren; Gunhan, Hatice Gizem; Erel, Pinar; Üstay, Özlem

doi:10.23736/s2724-6507.21.03465-5

Cited by 12 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TyG can easily and automatically be calculated from routine lab analysis and presented in lab reports. Interestingly, recent observational studies have shown that TyG can respond to interventions, being reduced upon initiation of treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors [ 27 ]. SGLT2 inhibitors provide impressive renal and cardiovascular beneficial effects, beyond the glycaemic control, in patients with diabetes and free from diabetes with CKD or heart failure [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Triglycerides–glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease

Quiroga

Ramos

Horrillo

et al. 2022

Clinical Kidney Journal

View full text Add to dashboard Cite

Background Chronic kidney disease (CKD) is associated to high rates of cardiovascular events. We here explored whether the recently described triglycerides-glucose index (TyG) predicted the incidence of major adverse cardiovascular events (MACE) in these patients. Methods Observational study of 1142 persons with CKD and free from diabetes and 460 controls from the prospective NEFRONA study. The study exposure was the TyG index at cohort inclusion. The study outcome was MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and hospitalization for unstable angina). Covariates included demographics, comorbidities, lipid profile, renal function and glycemic control. Cox regression models evaluated the association between TyG index and 4-point MACE in Patients with CKD. Results TyG was higher (median 8.63 IQR [8.32-8.95] in patients with CKD compared to controls (p<0.001). TyG increased across albuminuria categories but was similar for glomerular filtration rate categories among patients with CKD stages 3-5. During 46±13 months of follow-up, 49 (4.3%) MACE were registered. TyG predicted the occurrence of MACE (HR 1.95, 95%CI [1.11-3.40] per TyG unit increase; and HR 2.29, 95%CI [1.24-4.20] for TyG values above the median of 8.63 units). Sensitivity analysis for subgroups of participants according to age, kidney function, body mass index and imaging evidence of atherosclerosis yielded similar results, as did adjusted analysis. Neither triglycerides nor glucose alone were associated with MACE. Conclusions The TyG index is associated with the occurrence of major cardiovascular events in persons free from diabetes with non-dialysis dependent CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Triglycerides–glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease

Quiroga

Ramos

Horrillo

et al. 2022

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

“…Dapagliflozin is associated with an elevation of large, buoyant LDL particles (lb-LDL) and a decrease in small, dense LDL particles (sd LDLc), favouring the development of a less atherogenic lipid profile [ 31 ]. Decreases in several indices associated with CV disease, such as the plasma atherogenic index [log(TG/HDL-C)] or the triglyceride-glucose (TyG) index, have also been reported in patients treated with dapagliflozin [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

et al. 2022

View full text Add to dashboard Cite

Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.

show abstract

“…However, studies that have assessed changes in LDL-C fractions indicate that dapagliflozin treatment is associated with an increase in large, floating LDL particles with lower atherogenic potential, accompanied by a decrease in small, dense LDL particles, which are more associated with CV disease [ 33 ]. Recent studies have also described the association between dapagliflozin and a decrease in other markers associated with cardiovascular disease such as the plasma atherogenic index, defined as log(TG/HDL-C), or the triglyceride/glucose (TyG) index [ 34 ]. Overall, dapagliflozin would contribute to a less atherogenic lipid profile, by lowering the most atherogenic LDL fractions and increasing HDL-C.…”

Section: Resultsmentioning

confidence: 99%

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

et al. 2022

View full text Add to dashboard Cite

Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1.73 m 2 . As monotherapy or as an additive therapy, dapagliflozin has been shown to promote better glycaemic control, associated with a reduction in body weight and blood pressure in a wide range of patients. In addition, dapagliflozin has a positive impact on arterial stiffness, helps to control the lipid profile and contributes to a reduced risk of cardiovascular complications. This article reviews the current scientific evidence on the role of dapagliflozin in cardiovascular risk factors including arterial stiffness, cardiovascular disease and heart failure in patients with T2DM, with the aim of helping to translate this evidence into clinical practice. The underuse of SGLT2i in actual clinical practice is also discussed.

show abstract

SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study

Cited by 12 publications

References 39 publications

Triglycerides–glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease

Triglycerides–glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

Contact Info

Product

Resources

About